Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Robert Erik Holmlin M.B.A., Ph.D. | President, CEO & Director and CFO | 12.31M | -- | 1968 |
Mr. Mark Oldakowski | Chief Operating Officer | 9.51M | -- | 1974 |
Dr. Alka Chaubey FACMG, Ph.D. | Chief Medical Officer | 9.1M | -- | 1973 |
Mr. Mark Adamchak CPA | VP of Accounting & Controller | -- | -- | -- |
Mr. Jonathan Dixon J.D. | General Counsel & Secretary | -- | -- | 1975 |
Mr. Stanislas Marin M.B.A., M.S. | Vice President of Global Sales | -- | -- | -- |
Ms. Donna Polizio | Global Head of Market Access | -- | -- | -- |
Mr. Cory Kreeck | Global Head of People Operations | -- | -- | -- |
Bionano Genomics, Inc.
- Sector:
- Healthcare
- Industry: Medical Instruments & Supplies
- Full Time Employees:
- 98
Description
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. It also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic data from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, the company offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
May 6, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC
Bionano Genomics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available